Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Metacrine, Novo Nordisk to develop FGF1 variants

Alex Himes
August 15, 2017 10:03 PM UTC

Metacrine Inc. (San Diego, Calif.) partnered with Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to develop fibroblast growth factor 1 (FGF1) variants for glucose lowering and insulin sensitization.

Metacrine said it has developed a large library of FGF1 variants with improved "pharmaceutical properties." Under the deal, the biotech will continue certain research activities to further develop and characterize the FGF1 variants. Novo will have an option to license the FGF1 program after undisclosed research milestones are met...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Metacrine Inc.

Novo Nordisk A/S